Table 2.
Association between PTH slope/residuals/mean and mortality, by level of adjustment
| Exposure | N (%) | Model 1 | Model 2 | Model 3 | Model 3a |
|---|---|---|---|---|---|
| PTH slope (% change per month) | |||||
| Decreased > 15% | 2189 (8%) | 1.09 (0.97–1.22) | 1.08 (0.96–1.21) | 1.10 (0.98–1.25) | 1.13 (1.00–1.28) |
| Decreased 5–15% | 5479 (20%) | 1.12 (1.03–1.21) | 1.05 (0.97–1.14) | 1.06 (0.98–1.15) | 1.07 (0.98–1.16) |
| No change ±5% | 10,776 (40%) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Increased 5–15% | 5750 (21%) | 1.05 (0.97–1.13) | 1.04 (0.97–1.13) | 1.05 (0.97–1.13) | 1.03 (0.96–1.12) |
| Increased > 15% | 2594 (10%) | 1.07 (0.96–1.19) | 1.06 (0.95–1.18) | 1.08 (0.97–1.20) | 1.04 (0.93–1.16) |
| PTH mean squared residuals | |||||
| < 0.01 | 2967 (11%) | 0.98 (0.89–1.09) | 1.01 (0.91–1.13) | 1.01 (0.90–1.12) | 1.01 (0.90–1.13) |
| 0.01–0.05 | 6205 (23%) | 0.93 (0.86–1.01) | 0.94 (0.87–1.02) | 0.93 (0.86–1.01) | 0.94 (0.86–1.02) |
| 0.05–0.20 | 9481 (35%) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| 0.20–0.50 | 5043 (19%) | 1.02 (0.94–1.11) | 0.99 (0.91–1.08) | 1.00 (0.92–1.09) | 1.00 (0.92–1.09) |
| > 0.50 | 3092 (12%) | 0.95 (0.86–1.05) | 0.97 (0.88–1.08) | 0.98 (0.89–1.09) | 0.99 (0.89–1.11) |
| PTH geometric mean (pg/mL) | |||||
| < 100 | 2975 (11%) | 1.28 (1.16–1.41) | 1.01 (0.91–1.12) | 1.00 (0.90–1.11) | 0.99 (0.89–1.11) |
| 100–199 | 6395 (24%) | 1.09 (1.01–1.18) | 0.93 (0.86–1.00) | 0.92 (0.85–1.00) | 0.94 (0.87–1.02) |
| 200–399 | 10,887 (41%) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| 400–599 | 3666 (14%) | 0.92 (0.83–1.01) | 1.10 (1.00–1.22) | 1.11 (1.01–1.22) | 1.05 (0.95–1.17) |
| ≥ 600 | 2865 (11%) | 0.90 (0.81–1.00) | 1.33 (1.18–1.50) | 1.35 (1.20–1.52) | 1.19 (1.04–1.35) |
HR (95% CI) of all-cause mortality for each exposure displayed
Model 1: Stratified by phase, country, US-black race
Model 2: Model 1 + adjusted for age, sex, vintage, catheter use, 13 comorbidities, mean values of BMI, nPCR, Hgb, creatinine, albumin over 9-month run-in period
Model 3: Model 2 + simultaneous adjustment for all 3 exposures (PTH slope/residuals/mean)
Model 3a: Model 3 + adjusted for potential mediators: prescription of phosphate binders, cinacalcet, IV vitamin D, and oral vitamin D, P mean, (P mean)^2, P slope, Ca mean, and Ca slope over 9-month run-in period